About H1N1 vaccine, H1N1vaccine production, H1N1 vaccine manufacturers

Optimistic Prospect of Chinese A (H1N1) Influenza Vaccine Market

www.shcri.com — On the morning of September 14th, 2009, Hualan Biological Engineering Inc. declared that its clinical research on A (H1N1) influenza vaccine had been completed.

According to the clinical research of Hualan, 21 days after the first vaccine injection of 15 mcg, HI antibody levels of children, teenagers, adults and ancient people come up to 74.53%, 97.14%, 97.14% and 79.05% respectively; 21 days after the second injection, the antibody levels are improved to 99.01%, 100.00%, 97.96% and 96.08% respectively. Immunogenicity is in accordance with the standard of EU and America. Security research shows that the adverse effect rate is no higher than that of seasonal influenza vaccines.

China Ministry of Health claims to produce 13 million doses of vaccines before the end of September, 2009, covering 1% of Chinese population. The scale of Chinese A (H1N1) influenza vaccine market must exceed RMB 260 million. On September 4th, Sinovac Biotech Co., Ltd. and Hualan Biological Engineering Inc. were required by China Ministry of Industry and Information Technology to initially produce 3.3 million doses and 4 million doses respectively.

It is estimated that purchasing and stockpiling price of A (H1N1) influenza vaccines will be quite low. But the net profit rate will not be lower than common influenza vaccines, which is estimated to be about 60%. Price of Chinese common influenza vaccines is between RMB 20 and RMB 30 respectively.

Since autumn, spread of A (H1N1) influenza is been accelerated. According to the notice of China Ministry of Health on September 16th, 1,118 newly confirmed cases of A (H1N1) influenza appeared in Chinese mainland from 3 pm on September 14th to 3 pm on September 16th. 8 were offshore carriers and 1,110 were infected in mainland China. By September 16th, 10,221 confirmed cases were reported in 31 regions of Chinese mainland, including 6,098 cured ones.

Considering the acceleration of influenza spread, national purchasing and stockpiling volume of vaccines will be increased.

On August 21st, 2009, Minister of China Ministry of Health predicted that production of Chinese A (H1N1) influenza vaccines would cover 5% of Chinese population by the end of 2009. As there are 1.3 billion people in China, the first purchasing and stockpiling volume will be 65 million doses. It is regarded as the bottom line of vaccine production in 2009. If each dose is priced at RMB 20, the market scale will be RMB 1.3 billion at least in 2009.

Compared with other countries, Chinese population coverage ratio of A (H1N1) influenza vaccines is quite low (60% in America and 42% in Japan). Therefore, purchasing and stockpiling volume of vaccines will be improved to serve more people in China. It is predicted that the volume will be improved to over 1.3 trillion doses in 2009.

Four companies including Hualan have been authorized to produce A (H1N1) influenza vaccines. Another 6 companies are under examination and their production applications will be authorized soon. Clinical research on A (H1N1) influenza vaccine by Hualan has been completed. Productivity will be further enhanced.

Source: China Research and Intelligence

If you’d like to copy or quote this article, please keep the source information

For more information please visit:

http://www.shcri.com/reportdetail.asp?id=218

Contacts:

Eileen Gu

China Research and Intelligence

www.shcri.com

Email: eileen@shcri.com

TEL: 86-21-6852-1029 ext. 601

    86-21-6150-9706

MaximsNewsNetwork: 09 September 2009 – PAHO: The Brazilian Ministry of Health, in collaboration with the Butantã Institute in São Paulo, will start the production of around 17 million doses of the H1N1 vaccine in October 2009. The vaccines will be available at the beginning of 2010. Guaranteeing access for developing countries to vaccines, including a possible vaccine for the new influenza A(H1N1) virus, is a major concern of the Pan American Health Organization (PAHO), the regional office for the Americas of the World Health Organization (WHO). The Health Ministry of Brazil with the collaboration of the Butantan Institute in São Paulo, will start the production of around 17 million doses of the H1N1 vaccine in October 2009. The vaccines will be available at the start of 2010. In the meantime, PAHO says people should follow public health advice such as covering coughs and sneezes with a tissue, washing their hands frequently, and postponing travel if sick. Those who travel and return sick should seek medical advice. The Butantan Institute just finished building this new influenza vaccine plant that was plotted years ago in anticipation of a possible pandemic caused by a virus such as bird flu. It will now be exclusively devoted to full-scale production of the H1N1 vaccine. SOUNDBITE (Portuguese) Dr. Isais Raw, President, Institute Butantan: The Institute Butantan woke up four years ago when we started the construction of our influenza vaccine manufacturing plant. It is …
Video Rating: 5 / 5

Find More H1N1 Vaccine Production Articles

Related posts:

1. H1N1 vaccine production – Health officials expect long lines for H1N1 vaccinations
2. H1N1 vaccine production – H1N1 Update
3. H1N1 vaccine production – Kaiser waiting in line like everyone else for H1N1 vaccine
4. H1N1 vaccine production – H1N1 Swine Flu Vaccine…. What Are The Pros And Cons And What Are “your” Options?
5. H1N1 vaccine production – The 10 Most Common Swine Flu (H1N1) Myths…You Better Know What They Are